Forty Seven Finds $32.5M For Cancer Antibodies
Palo Alto-based Forty Seven Inc., which is developing antibodies aimed at attacking cancer tumors, has raised the first half of a $75M in a Series A financing, the company said today. The company said the Series A was led by Lightspeed Venture Partners and Sutter Hill Ventures along with Clarus Ventures and GV (formerly Google Ventures). The company has licensned imuno-oncology programs from Stanford. The company's lead compound is Hu5F9-G4, a humanized monoclonal antibody against human CD47 that the company says has broad applications spanning multiple tumor types and treatment modalities.
posted on Wednesday, February 24, 2016 (Link to more information)
Related companies:
Forty Seven Inc.
Related stories:
> Forty Seven Finds $75M For Cancer Drugs
> Igenica Raises $33M For Cancer Antibodies
> POC Medical Systems Finds $21M For Breast Cancer Screening
> Guardant Health Finds $50M
> KaloBios Pharmaceuticals Raises $12M
silicontap.com Home